DBV Technologies S.A.

NASDAQ:DBVT

Biotechnology

Healthcare
$9.99 -0.95%

-$0.16 today

Market cap
$238.98M
Beta
-0.22
P/E (TTM)
-8.3
EPS (TTM)
-$0.39
52W Low $8.50High $26.19

Volume 0.17M

Average 0.24M

Returns on capital

DBV Technologies S.A. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-87.1%

avg -103.7%

ROIC

-76.6%

avg -88.6%

ROA

-62.9%

avg -64.3%

Analysis

ROA is currently the strongest return metric at -62.9% versus its period average of -64.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daniel Tassé

Chief Executive Officer & DirectorUSD 1.44M66964.00K4.03%

Pharis Mohideen

Chief Medical OfficerUSD 1.02M61144.53K0.60%

Virginie Simone Jeanine Verrechia Boucinha

Chief Financial OfficerUSD 600.14K57——

Alan Kerr

Senior Vice President & Head of Global Regulatory Affairs————

Kevin Malobisky

Chief Operations Officer————

Robert G. Pietrusko D.

Chief Regulatory Officer—78——

James Briggs

Chief Human Resources Officer—54——

Jonathan Neely

VP & Head of Investor Relations————

Kevin Trapp

Chief Commercial Officer—59——

Pascal Wotling

Chief External Manufacturing & Supply Chain Officer————

Michele F. Robertson

Chief Legal Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 29, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

7

$15.51M

Net Transaction Value

−$15.51M

Net selling

Most Active

Mohideen Pharis

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 29, 26

Mohideen Pharis

Direct

Sell$1.3K
Jan 29, 26

Mohideen Pharis

Direct

Sell$2.6K
Dec 18, 25

EPIC Bpifrance

Indirect

Sell$5.4M
Dec 17, 25

EPIC Bpifrance

Indirect

Sell$9.9M
Dec 17, 25

EPIC Bpifrance

Indirect

Sell$211.2K
Nov 21, 25

Mohideen Pharis

Direct

Sell$4.5K
Nov 20, 25

Mohideen Pharis

Direct

Sell$18.7K

Summary

Insiders reported 0 buys worth $0.00 and 7 sells worth $15.51M over the last 12 months. That adds up to net selling of $15.51M. Mohideen Pharis was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does DBV Technologies S.A. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DBVT's management, answered from reported figures.

Who manages DBVT?

DBV Technologies S.A. (DBVT) lists 11 active executives. The top listed executive is Alan Kerr, Senior Vice President & Head of Global Regulatory Affairs.

Are DBVT insiders buying or selling?

Recent insider activity shows net selling of $334,641.00.